Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Non-Current Assets (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Non-Current Assets for 6 consecutive years, with $43.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 30.66% to $43.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $197.2 million, a 26.06% decrease, with the full-year FY2025 number at $43.1 million, down 30.66% from a year prior.
  • Non-Current Assets was $43.1 million for Q4 2025 at Relay Therapeutics, down from $46.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $81.4 million in Q3 2022 to a low of $28.9 million in Q1 2021.
  • A 5-year average of $56.3 million and a median of $60.9 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 151.64% in 2022, then plummeted 30.66% in 2025.
  • Relay Therapeutics' Non-Current Assets stood at $32.2 million in 2021, then skyrocketed by 149.27% to $80.3 million in 2022, then decreased by 7.96% to $73.9 million in 2023, then dropped by 15.95% to $62.1 million in 2024, then tumbled by 30.66% to $43.1 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Non-Current Assets are $43.1 million (Q4 2025), $46.0 million (Q3 2025), and $48.4 million (Q2 2025).